Gastrin I (human): Applications in Organoid and GI Physiology Research

Introduction

Understanding the regulatory mechanisms of gastric acid secretion is fundamental to gastrointestinal physiology and disease research. Gastrin I (human) is a key endogenous peptide involved in these processes, acting as a potent gastric acid secretion regulator through its action as a CCK2 receptor agonist. Recent advances in human stem cell-derived intestinal organoids have created new opportunities to dissect the molecular underpinnings of gastrointestinal function and pathophysiology. This article examines the utility of human Gastrin I peptide in experimental systems, with a special focus on organoid models and receptor-mediated signal transduction pathways, positioning the peptide as a critical tool for advanced gastrointestinal disorder research.

The Molecular Role of Gastrin I (human) in Gastric Acid Secretion

Gastrin I (human), with a molecular weight of 2098.22 Da (CAS: 10047-33-3), is a 17-amino acid peptide hormone produced by G cells in the gastric antrum. Its primary physiological function is to stimulate gastric acid secretion by binding to the cholecystokinin B/gastrin receptor (CCK2 receptor) on gastric parietal cells. Upon receptor engagement, Gastrin I activates intracellular signaling cascades, notably the Gq/PLC pathway, resulting in increased intracellular calcium and subsequent activation of the H⁺/K⁺-ATPase proton pump. This sequence of events drives acid secretion into the gastric lumen, a process central to digestive physiology and the pathogenesis of acid-related disorders.

The specificity of Gastrin I for the CCK2 receptor and its resistance to rapid degradation make it an invaluable reagent for probing receptor-mediated signal transduction. In vitro, the peptide is widely used to precisely modulate gastric acid secretion pathways, facilitating mechanistic studies that delineate the contributions of proton pump activation and downstream signaling molecules.

Advancing Gastrointestinal Physiology Studies Using Organoid Models

Traditional models of gastrointestinal research, such as rodent systems or immortalized cell lines (e.g., Caco-2), often fall short in recapitulating the complexity of human tissue physiology, especially regarding gastric acid secretion pathway research. The emergence of human pluripotent stem cell (hPSC)-derived intestinal organoids represents a significant methodological leap. These 3D structures retain self-renewal and differentiation capacities characteristic of intestinal stem cells and their progeny, including enterocytes and enteroendocrine cells, offering a physiologically relevant platform for functional studies (Saito et al., European Journal of Cell Biology, 2025).

Recent work by Saito and colleagues established protocols for deriving intestinal organoids from human induced pluripotent stem cells (hiPSCs), enabling the generation of mature intestinal epithelial cells (IECs) with functional cytochrome P450 activity and drug transporter expression. These organoid-derived IECs are particularly suited for pharmacokinetic studies and for modeling the intricate interactions among hormones, receptors, and signaling pathways in the gastrointestinal tract. Importantly, the inclusion of peptides such as Gastrin I (human) in these systems allows researchers to simulate physiologically relevant stimuli and track the activation of the CCK2 receptor signaling axis within a human context.

Experimental Applications: From Signal Transduction to Disease Modeling

Human Gastrin I peptide is especially valuable for dissecting receptor-mediated signal transduction in both native and engineered gastrointestinal epithelia. For instance, in organoid cultures, application of Gastrin I can be leveraged to:

• Quantify CCK2 receptor responsiveness and downstream calcium signaling.
• Assess the regulation and kinetics of proton pump activation in parietal cell-like populations.
• Investigate cross-talk between acid secretion and other epithelial functions, such as mucus production or hormone release.
• Evaluate pharmacological agents targeting the CCK2 receptor or H⁺/K⁺-ATPase in the context of human gastrointestinal physiology.

Furthermore, these models are instrumental for gastrointestinal disorder research. Conditions such as Zollinger-Ellison syndrome, peptic ulcer disease, and gastric carcinogenesis involve dysregulation of gastrin signaling and acid secretion. By introducing Gastrin I (human) into organoid or monolayer systems, researchers can recapitulate disease-relevant phenotypes and test therapeutic interventions under controlled, human-specific conditions.

Technical Considerations for In Vitro Use

Experimental reliability depends on the biochemical quality and handling of Gastrin I (human). The peptide is supplied as a high-purity (≥98%, validated by HPLC and mass spectrometry), lyophilized solid, designed for research use. It is insoluble in water and ethanol but dissolves readily in DMSO at concentrations ≥21 mg/mL. For optimal stability, it should be stored desiccated at -20°C, with solutions prepared immediately before use to avoid degradation. These properties make it suitable for acute stimulation experiments, dose-response assays, and real-time imaging of receptor-mediated events in live cell or organoid preparations.

Translational Perspectives: Linking Gastrin I Signaling to Pharmacokinetics

Beyond its classical function in acid secretion, Gastrin I (human) is increasingly recognized for its broader regulatory effects on gastrointestinal physiology. In the context of organoid-based pharmacokinetic studies, as highlighted by Saito et al. (2025), modulation of CCK2 receptor signaling may influence not only epithelial cell function but also drug absorption, metabolism, and transporter activity. These findings underscore the relevance of including peptides such as Gastrin I in next-generation in vitro models to more accurately predict human responses to pharmaceutical agents.

Moreover, the ability to interrogate proton pump activation and its regulation in organoids enables researchers to explore the interplay between hormone signaling and the pharmacodynamics of acid-suppressive therapies, such as proton pump inhibitors or H₂ receptor antagonists, within a humanized tissue context.

Integrative Approaches: Combining Gastrin I with Multi-Omic and Imaging Technologies

The mechanistic insights provided by Gastrin I (human) stimulation can be further amplified by integrating multi-omic (transcriptomic, proteomic, phosphoproteomic) analyses and advanced imaging techniques. For example, real-time calcium flux imaging or single-cell RNA sequencing following Gastrin I treatment enables high-resolution mapping of CCK2 receptor signaling heterogeneity across different cell types within organoids. Such approaches are pivotal for identifying novel regulatory nodes in gastric acid secretion pathway research and for unraveling the molecular basis of inter-individual variability in gastrointestinal responses.

Practical Guidance: Experimental Design and Troubleshooting

For experimental systems utilizing Gastrin I (human), careful titration of peptide concentration and exposure time is essential to model physiological versus pathological conditions. Researchers should consider the composition of the culture medium (e.g., presence of serum or growth factors), the differentiation status of the epithelium, and the expression profile of the CCK2 receptor. In organoid systems, pre-treatment with receptor antagonists or proton pump inhibitors can provide critical controls to confirm the specificity of observed responses. When planning multi-parameter readouts (e.g., acid secretion, gene expression, signaling activation), parallel vehicle-treated controls and time-course experiments are recommended for robust interpretation.

Conclusion

Gastrin I (human) is a foundational tool for dissecting the regulation of gastric acid secretion, CCK2 receptor signaling, and receptor-mediated signal transduction in contemporary gastrointestinal physiology studies. Its application in advanced in vitro models, especially human stem cell-derived organoids, enables detailed exploration of proton pump activation and the mechanisms underlying gastrointestinal disorders. As demonstrated by recent work on organoid pharmacokinetics (Saito et al., 2025), integration of Gastrin I into experimental designs enhances the translational value of these systems for drug evaluation and disease modeling.

Contrast with Existing Literature

While previous articles such as "Gastrin I (human): A Versatile Tool for Gastric Acid Secr..." have focused on classical applications of Gastrin I in gastric acid secretion assays, the current review uniquely emphasizes the integration of Gastrin I into human organoid platforms and the implications for pharmacokinetic and translational research. By detailing methodological innovations and the intersection with stem cell biology, this article extends the utility of human Gastrin I peptide beyond traditional contexts, offering new perspectives for gastrointestinal disorder research and next-generation experimental models.